Suppr超能文献

巴西癌症的卫生经济评估:一项系统综述。

Health Economic Evaluations of Cancer in Brazil: A Systematic Review.

作者信息

Campolina Alessandro G, Yuba Tania Y, Decimoni Tassia C, Leandro Roseli, Diz Maria Del Pilar Estevez, Novaes Hillegonda M D, de Soárez Patrícia C

机构信息

Department of Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

出版信息

Front Public Health. 2018 Jul 27;6:205. doi: 10.3389/fpubh.2018.00205. eCollection 2018.

Abstract

UNLABELLED

A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied.

OBJECTIVE

To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context. A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013). Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO). There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.

摘要

未标注

大量卫生经济评估(HEE)研究已在发达国家发表。然而,巴西肿瘤学领域的卫生经济评估文献尚未得到研究。

目的

调查科学文献是否提供了一组肿瘤学方面的卫生经济评估,能够支持巴西背景下的决策制定。进行了一项系统综述,以识别和描述该领域的研究。我们在多个数据库中进行搜索,选择了1998年至2013年期间肿瘤学方面的部分和完整卫生经济评估研究。共审查了55篇文章,其中33篇(60%)为完整的卫生经济评估。研究最多的癌症类型为:乳腺癌(38.2%)、宫颈癌(14.6%)、肺癌(10.9%)和结直肠癌(9.1%)。程序(47.3%)是最常评估的技术。就技术的预期目的而言,大多数(63.6%)是治疗方法。报告的大多数增量成本效益比(ICER)低于世界卫生组织(WHO)建议的成本效益阈值。巴西与癌症相关的卫生经济评估数量有所增加。这些研究可能支持巴西癌症治疗医疗技术覆盖范围和报销方面的决策过程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8be7/6072849/20ee23c11b5b/fpubh-06-00205-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验